Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Year: 2025
Type: article
Language: en
Topic: Prostate Cancer Treatment and Research
Authors and affiliations:
raw_author_name: Neal D. Shore
raw_affiliation_strings: START Carolinas/Carolina Urologic Research Center, Myrtle Beach, South Carolina
raw_author_name: Martin Gleave
raw_affiliation_strings: Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
raw_author_name: Ugo De Giorgi
raw_affiliation_strings: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy
raw_author_name: Antti Rannikko
raw_affiliation_strings: Department of Urology and Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland
Helsinki University Hospital, Helsinki, Finland
raw_author_name: Christopher M. Pieczonka
raw_affiliation_strings: Clinical Research, US Urology Partners and Associated Medical Professionals of New York, PLLC, Syracuse, New York
raw_author_name: Swetha Sridharan
raw_affiliation_strings: Department of Radiation Oncology, Calvary Mater, Newcastle, New South Wales, Australia
raw_author_name: Klaus Brasso
raw_affiliation_strings: Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
raw_author_name: Henry H. Woo
raw_affiliation_strings: Department of Uro-Oncology, Chris O’Brien Lifehouse, Camperdown, New South Wales, Australia
Department of Urology, Blacktown and Mount Druitt Hospitals, Blacktown,, New South Wales, Australia
raw_author_name: Antonio Gómez Caamaño
raw_affiliation_strings: Department of Radiation Oncology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
raw_author_name: Jeff W. Saranchuk
raw_affiliation_strings: Manitoba Prostate Centre CancerCare, Manitoba, Winnipeg, Canada
raw_author_name: Luke T. Nordquist
raw_affiliation_strings: XCancer/Urology Cancer Center, Omaha, NE, USA
raw_author_name: Ubirajara Ferreira
raw_affiliation_strings: Department of Urology, State University of Campinas, Campinas, Brazil
raw_author_name: Yiyun Tang
raw_affiliation_strings: Global Product Development, Pfizer Inc., South San Francisco, California
raw_author_name: Brad Rosbrook
raw_affiliation_strings: Global Product Development, Pfizer Inc., La Jolla, California
raw_author_name: Gabriel P. Haas
raw_affiliation_strings: Global Product Development, Astellas Pharma Inc., Northbrook, Illinois
raw_author_name: Matt Rosales
raw_affiliation_strings: Astellas Pharma Global Development, Northbrook, Illinois
raw_author_name: Fabian Zohren
raw_affiliation_strings: Global Product Development, Pfizer Inc., Cambridge, Massachusetts
raw_author_name: Jamal Tarazi
raw_affiliation_strings: Global Product Development, Pfizer Inc., Collegeville, Pennsylvania
raw_author_name: Stephen J. Freedland
raw_affiliation_strings: Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Durham VA Medical Center, Durham, North Carolina, USA